Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: Utility and incentives

Alzheimer's and Dementia

Volumn 5, Issue 2, 2009, Pages 108-113

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; BIOLOGICAL MARKER; GAMMA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL RESEARCH; DISEASE COURSE; DRUG APPROVAL; EDITORIAL; FACTUAL DATABASE; HUMAN; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; ENDPOINT DETERMINATION; HEALTH POLICY; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; UNITED STATES;

EID: 62849084323     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.01.015     Document Type: Editorial

References (18)

1. Salloway S., Mintzer J., Weiner M.F., and Cummings J.L. Disease-modifying therapies in Alzheimer's disease. Alzheimers & Dementia 4 (2008) 65-79
2. Cummings J.L. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers & Dementia 2 (2006) 263-271
3. Cummings J.L. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers & Dementia 4 (2008) S15-S20
4. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust C.R., et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1 (2005) 55-66
5. Jack Jr. C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27 (2008) 685-691
6. Nestor S.M., Rupsingh R., Borrie M., Smith M., Accomazzi V., Wells J.L., et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131 (2008) 2443-2454
7. Ridha B.H., Anderson V.M., Barnes J., Boyes R.G., Price S.L., Rossor M.N., et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol 255 (2008) 567-574
8. De Gruttola V.G., Clax P., DeMets D.L., Downing G.J., Ellenberg S.S., Friedman L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485-502
9. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 282 (1999) 790-795
10. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1 (2004) 189-195
11. Feigin A. Evidence from biomarkers and surrogate endpoints. NeuroRx 1 (2004) 323-330
12. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 (2006) 228-234
13. Lewczuk P., Hornegger J., Zimmermann R., Otto M., Wiltfang J., and Kornhuber J. Neurochemical dementia diagnostics: assays in CSF and blood. Eur Arch Psychiatry Clin Neurosci 258 (2008) S44-S49
14. Grimmer T., Henriksen G., Wester H.J., Förstl H., Klunk W.E., Mathis C.A., et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging (2008;Mar 16) [Epub ahead of print]
15. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (2008) 1630-1645
16. Bouwman F.H., van der Flier W.M., Schoonenboom N.S., van Elk E.J., Kok A., Rijmen F., et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69 (2007) 1006-1011
17. Wu G., Sankaranarayanan S., Tugusheva K., Kahana J., Seabrook G., Shi X.P., et al. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem 41 (2008) 986-996
18. Bateman R.J., and Klunk W.E. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics 5 (2008) 381-390